Chf10196

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

8 competitors in Male

#DrugCompanyPhaseTrials

1

Sensipar

Amgen

Approved

12

Crestor

AstraZeneca

Phase 1

—3

Pradaxa

Boehringer Ingelheim

Phase 1

—4

Romvimza

DDeciphera Pharmaceuticals, LLC

Phase 1

—5

Pradaxa

Boehringer Ingelheim

Phase 1

—6

Chf10196

Chiesi Farmaceutici S.p.A.

Phase 1

2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Unspecified2 trials

An Open-label, Fixed-sequence, Non-randomized, Drug-drug Interaction Study to Evaluate the Effect of CHF10196 on the Pharmacokinetics of Dabigatran (P-gp Substrate) and Rosuvastatin (BCRP Substrate) in Healthy Male Participants.

Not yet recruiting·Chiesi Farmaceutici S.p.A.·Phase 1·NCT07744386·24 enrolled

An Open-label, Fixed-sequence, Non-randomised, Drug-drug Interaction Study to Evaluate the Effect of Pantoprazole (Proton Pump Inhibitor) on the Pharmacokinetics of CHF10196 in Healthy Male Participants.

Not yet recruiting·Chiesi Farmaceutici S.p.A.·Phase 1·NCT07683793·18 enrolled

Details

Drug Info

Related News